EMEA-001646-PIP01-14-M02
Key facts
Invented name |
Epclusa
|
Active substance |
|
Therapeutic area |
Infectious diseases
|
Decision number |
P/0150/2018
|
PIP number |
EMEA-001646-PIP01-14-M02
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of chronic hepatitis C
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Gilead Sciences International Ltd
E-mail: regulatory.pip@gilead.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-001646-PIP01-14-M02
|
Compliance opinion date |
26/02/2021
|
Compliance outcome |
positive
|